慢性閉塞性肺疾患（COPD）治療の世界市場レポート 2025年

慢性閉塞性肺疾患（COPD）治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で277億4,000万米ドルに成長します。予測期間の成長は、個別化医療とバイオマーカー研究、生物学的療法と標的介入、大気質への懸念と環境要因、禁煙のための世界的な取り組み、医薬品開発のための共同研究などに起因すると考えられます。予測期間の主な動向には、COPD管理のためのデジタルヘルスソリューション、COPDの生物学的療法、個別化医療の登場、併用療法と吸入器、早期診断と介入、肺リハビリテーションプログラムなどが含まれます。

慢性閉塞性肺疾患（COPD）治療市場の成長予測は、肺機能に悪影響を及ぼす疾患である肺疾患の有病率の増加によって後押しされています。喘息、COPD、肺がんを含む肺疾患は広く蔓延しており、世界中で数百万人が罹患しています。COPD治療は、吸入器や薬剤の使用を通じて症状を管理し、病気の進行を遅らせ、肺の損傷を予防することにより、肺疾患に対処する上で重要な役割を果たしています。例えば、2022年9月現在、Global Initiative for Chronic Obstructive Lung Disease（GOLD）は、年間320万人がCOPDに罹患し、約2億人が影響を受けていると報告しています。さらに、2022年の喘息の世界的有病率は2億6,200万人に達し、LUNGevity Foundationは、2023年までに米国だけで肺がんが年間12万7,000人の死因になると予測しています。このような肺疾患の有病率の増加がCOPD治療市場の成長を後押ししています。

慢性閉塞性肺疾患（COPD）治療市場は、喫煙率の上昇によってさらに影響を受けています。喫煙は、特にタバコのような燃焼物質からの煙の吸入を伴い、呼吸器疾患やCOPDの重大な原因となっています。COPDの治療は、呼吸の改善、生活の質の向上、増悪の抑制、運動耐容能の向上、寿命の延長、精神衛生の改善などを目的として、喫煙者の間でますます求められるようになっています。2023年7月現在、世界保健機関（WHO）の報告書によると、タバコに関連した死亡者数は年間800万人を超え、非喫煙者の130万人が副流煙の影響を受けています。したがって、喫煙率の上昇は、COPD治療市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の慢性閉塞性肺疾患（COPD）治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の慢性閉塞性肺疾患（COPD）治療市場：成長率分析
• 世界の慢性閉塞性肺疾患（COPD）治療市場の実績：規模と成長、2019～2024年
• 世界の慢性閉塞性肺疾患（COPD）治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の慢性閉塞性肺疾患（COPD）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性閉塞性肺疾患（COPD）治療市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• 併用療法
• 気管支拡張薬
• コルチコステロイド
• ホスホジエステラーゼ4阻害剤
• 粘液動態
• その他
• 世界の慢性閉塞性肺疾患（COPD）治療市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 慢性気管支炎
• 肺気腫
• 世界の慢性閉塞性肺疾患（COPD）治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• ホームケア設定
• 世界の慢性閉塞性肺疾患（COPD）治療市場：併用療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 長時間作用型β刺激薬（LABA）+吸入コルチコステロイド（ICS）
• 長時間作用型ムスカリン拮抗薬（LAMA）+LABA
• ３剤療法（LAMA+LABA+ICS）
• 世界の慢性閉塞性肺疾患（COPD）治療市場：気管支拡張薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 短時間作用型β刺激薬（SABA）
• 長時間作用型β刺激薬（LABA）
• 長時間作用型ムスカリン拮抗薬（LAMA）
• 世界の慢性閉塞性肺疾患（COPD）治療市場：コルチコステロイドのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 吸入コルチコステロイド（ICS）
• 経口コルチコステロイド
• 注射用コルチコステロイド
• 世界の慢性閉塞性肺疾患（COPD）治療市場：ホスホジエステラーゼ4阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ロフルミラスト
• その他のPDE4阻害剤
• 世界の慢性閉塞性肺疾患（COPD）治療市場：粘液動態のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 去痰薬
• 粘液溶解薬
• 世界の慢性閉塞性肺疾患（COPD）治療市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗生物質
• 抗ウイルス薬
• 抗真菌剤

第7章 地域別・国別分析

• 世界の慢性閉塞性肺疾患（COPD）治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の慢性閉塞性肺疾患（COPD）治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性閉塞性肺疾患（COPD）治療市場：競合情勢
• 慢性閉塞性肺疾患（COPD）治療市場：企業プロファイル
  • Almirall S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Abbott Laboratories
• Chiesi Farmaceutici S.p.A
• Mylan N.V.
• Orion Corporation
• Sunovion Pharmaceuticals Inc.
• Dr. Reddy's Laboratories Ltd.
• Circassia Group PLC
• Kyowa Kirin Co. Ltd.
• Sanofi S.A
• Theravance Biopharma Inc.
• Verona Pharmaceuticals plc
• Alcon Laboratories Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 慢性閉塞性肺疾患（COPD）治療市場2029年：新たな機会を提供する国
• 慢性閉塞性肺疾患（COPD）治療市場2029年：新たな機会を提供するセグメント
• 慢性閉塞性肺疾患（COPD）治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chronic obstructive pulmonary disease (COPD) treatment encompasses medical interventions aimed at symptom management, progression mitigation, and overall quality of life improvement for individuals with COPD. COPD, characterized by airflow obstruction, chronic inflammation, and lung tissue damage, requires a comprehensive approach to medical care.

Key pharmaceutical interventions in chronic obstructive pulmonary disease (COPD) treatment include combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and other drug classes. Combination therapy involves the administration of multiple therapies to address the complex nature of COPD. This approach entails providing patients with a range of tablets, each containing specific medications. Widely utilized in the treatment of conditions such as chronic bronchitis and emphysema, combination therapy is prevalent in healthcare settings, including hospitals, clinics, and homecare, as part of the COPD treatment regimen.

The chronic obstructive pulmonary disease (COPD) treatment market research report is one of a series of new reports from The Business Research Company that provides chronic obstructive pulmonary disease (COPD) treatment market statistics, including chronic obstructive pulmonary disease (COPD) treatment industry global market size, regional shares, competitors with a chronic obstructive pulmonary disease (COPD) treatment market share, detailed chronic obstructive pulmonary disease (COPD) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (COPD) treatment industry. This chronic obstructive pulmonary disease (COPD) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic obstructive pulmonary disease (COPD) treatment market size has grown strongly in recent years. It will grow from$20.84 billion in 2024 to $21.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to smoking epidemic and tobacco use, advancements in inhalation therapies, awareness programs and early diagnosis, government initiatives for respiratory health, research and development in pulmonology

The chronic obstructive pulmonary disease (COPD) treatment market size is expected to see strong growth in the next few years. It will grow to $27.74 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine and biomarker research, biologic therapies and targeted interventions, air quality concerns and environmental factors, global efforts for smoking cessation, collaborations for drug development. Major trends in the forecast period include digital health solutions for COPD management, biologic therapies for COPD, emergence of personalized medicine, combination therapies and inhalers, early diagnosis and intervention, pulmonary rehabilitation programs.

The growth projections for the chronic obstructive pulmonary disease (COPD) treatment market are fueled by the increasing prevalence of lung disease, a condition that adversely impacts lung function. Lung diseases, including asthma, COPD, and lung cancer, are widespread, affecting millions globally. COPD treatment plays a crucial role in addressing lung diseases by managing symptoms, slowing disease progression, and preventing lung damage through the use of inhalers and medications. For example, as of September 2022, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) reported that 3.2 million people succumb to COPD annually, impacting approximately 200 million individuals. Additionally, the prevalence of asthma globally in 2022 reached 262 million people, and the LUNGevity Foundation projected that lung cancer would cause 127,000 annual deaths in the US alone by 2023. This increasing prevalence of lung diseases propels the growth of the COPD treatment market.

The trajectory of the chronic obstructive pulmonary disease (COPD) treatment market is further influenced by the rising prevalence of smoking. Smoking, involving the inhalation of smoke, particularly from burning substances such as tobacco, is a significant contributor to respiratory issues and COPD. Treatment for COPD is increasingly sought after by individuals who smoke, aiming to enhance breathing, improve quality of life, reduce exacerbations, enhance exercise tolerance, increase longevity, and improve mental health. As of July 2023, a report from The World Health Organization revealed that tobacco-related deaths exceed 8 million annually, with 1.3 million non-smokers affected by second-hand smoke inhalation. The escalating prevalence of smoking underscores the driving force behind the growth of the COPD treatment market.

A notable trend in the chronic obstructive pulmonary disease (COPD) treatment market is the emphasis on product innovation by major industry players. Companies operating in this market are actively engaged in the development of innovative products to strengthen their market position. For example, in April 2022, GlaxoSmithKline plc (GSK), a leading UK-based pharmaceutical and biotechnology company, introduced Trelegy Ellipta-a groundbreaking single-inhaler triple treatment (SITT) for patients with COPD in India. Trelegy Ellipta, comprising fluticasone furoate, umeclidinium, and vilanterol, serves as a maintenance medication for treating and preventing COPD symptoms in individuals aged 18 and older. The product's mechanism involves mimicking natural corticosteroid hormones, reducing immune system activity, and alleviating airway swelling for improved breathing.

Innovative product development continues to be a strategic focus for major companies in the COPD treatment market, exemplified by offerings such as Vilfuro-G. Launched by Lupin Limited, an India-based pharmaceutical company in November 2023, Vilfuro-G stands as the world's first fixed-dose triple combination medication (FDC) designed to effectively treat COPD. With a fixed, once-daily dosage, Vilfuro-G is expected to significantly enhance the lives of COPD patients, expanding Lupin's respiratory product line and showcasing the company's commitment to delivering cutting-edge treatment options. As the only FDC tailored to combine glycopyrronium bromide, vilanterol, and fluticasone furoate, Vilfuro-G addresses the long-term treatment and management of moderate to severe COPD.

In March 2023, a collaboration between UC Davis Health, a US-based health system, and Propeller Health, a US-based digital health company specializing in respiratory health, further exemplifies the trend of integrating digital health technologies into COPD treatment. This partnership aims to utilize Propeller's remote monitoring program, incorporating sensors, a mobile app, a web interface, and personalized support to deliver individualized treatment for high-risk patients with chronic respiratory illnesses such as asthma and COPD. This collaboration underscores a commitment to leveraging digital health solutions to enhance clinical outcomes and improve care for individuals with chronic conditions.

Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.

North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the chronic obstructive pulmonary disease (copd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The chronic obstructive pulmonary disease (COPD) treatment market includes revenues earned by entities by providing services such as oxygen therapy, pulmonary rehabilitation, medication services, endobronchial valve therapy and non-invasive ventilation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic obstructive pulmonary disease (copd) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic obstructive pulmonary disease (copd) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic obstructive pulmonary disease (copd) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Combination Therapy; Bronchodilators; Corticosteroids; Phosphodiesterase Type 4 Inhibitor; Mucokinetics; Other Drug Classes
• 2) By Type: Chronic Bronchitis; Emphysema
• 3) By End-User: Hospitals; Clinics; Homecare Settings
• Subsegments:
• 1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS); Long-Acting Muscarinic Antagonists (LAMA) + LABA; Triple Therapy (LAMA + LABA + ICS)
• 2) By Bronchodilators: Short-Acting Beta-Agonists (SABA); Long-Acting Beta-Agonists (LABA); Long-Acting Muscarinic Antagonists (LAMA)
• 3) By Corticosteroids: Inhaled Corticosteroids (ICS); Oral Corticosteroids; Injectable Corticosteroids
• 4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast; Other PDE4 Inhibitors
• 5) By Mucokinetics: Expectorants; Mucolytics
• 6) By Other Drug Classes: Antibiotics; Antivirals; Antifungal Agents
• Companies Mentioned: Almirall S.A.; AstraZeneca plc; Boehringer Ingelheim International GmbH; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Characteristics

3. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends And Strategies

4. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Rate Analysis
• 5.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Total Addressable Market (TAM)

6. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Segmentation

• 6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Therapy
• Bronchodilators
• Corticosteroids
• Phosphodiesterase Type 4 Inhibitor
• Mucokinetics
• Other Drug Classes
• 6.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Bronchitis
• Emphysema
• 6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• 6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS)
• Long-Acting Muscarinic Antagonists (LAMA) + LABA
• Triple Therapy (LAMA + LABA + ICS)
• 6.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Acting Beta-Agonists (SABA)
• Long-Acting Beta-Agonists (LABA)
• Long-Acting Muscarinic Antagonists (LAMA)
• 6.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhaled Corticosteroids (ICS)
• Oral Corticosteroids
• Injectable Corticosteroids
• 6.7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Phosphodiesterase Type 4 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Roflumilast
• Other PDE4 Inhibitors
• 6.8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Mucokinetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Expectorants
• Mucolytics
• 6.9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antivirals
• Antifungal Agents

7. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Regional And Country Analysis

• 7.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 8.1. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 9.1. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 9.2. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 10.1. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 11.1. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 11.2. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 12.1. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 13.1. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 14.1. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 14.2. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 15.1. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 15.2. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 16.1. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 17.1. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 18.1. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 19.1. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 20.1. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 21.1. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 21.2. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 22.1. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 23.1. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 23.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 24.1. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 24.2. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 25.1. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 25.2. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 26.1. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 26.2. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 27.1. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 28.1. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 28.2. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

• 29.1. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
• 29.2. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competitive Landscape
• 30.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Company Profiles
  • 30.2.1. Almirall S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Astellas Pharma Inc.
• 31.4. Abbott Laboratories
• 31.5. Chiesi Farmaceutici S.p.A
• 31.6. Mylan N.V.
• 31.7. Orion Corporation
• 31.8. Sunovion Pharmaceuticals Inc.
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Circassia Group PLC
• 31.11. Kyowa Kirin Co. Ltd.
• 31.12. Sanofi S.A
• 31.13. Theravance Biopharma Inc.
• 31.14. Verona Pharmaceuticals plc
• 31.15. Alcon Laboratories Inc.

32. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

34. Recent Developments In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

35. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer